VEEV — Veeva Systems Inc.
Healthcare · ETF XLV · as of 2026-09-18
Daily · EMA 10 / 20 / 50 · SMA 200 · VolPress: buy/sell split, 20-SMA, white dot = above avg · · E = earnings · RS vs SPY ⓘ · ● RS new high ⓘ
Veeva Systems Inc.
NYQ
Healthcare · Health Information Services
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
Price & today
$260.21
ATR(14) 9.08 (3.49%)
| Stock today | -1.34% |
| Sector ETF today | -0.25% |
| Residual (stock-specific) | -1.09% |
Sector correlation
| 20-day correlation with XLV | -0.04 |
| 60-day correlation with XLV | 0.33 |
| Status | DECOUPLING |
Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.
Technicals
| 10 EMA | $264.58 |
| 20 EMA | $260.86 |
| 50 EMA | $239.08 |
| EMA stack | BULLISH |
| RSI(14) | 53.7 |
| 52-week high distance | -16.20% |
| 52-week low distance | +75.76% |
Signals
| Market F&G | 46.9 |
| Bull% | 12.2% |
| OVTLYR status | SELL (6d) |
| Sector rank | #538 |
| Next earnings | 2026-11-18 (AMC, 60d) |
MarketSmith metrics - our compute
RS Rating
83.4
ADR%
3.1
RMV (tight)
0.0
Ext (ATR>20EMA)
-0.1
Rel Vol
340.0%
U/D 50d
1.71
U/D 25d
0.87
Accum/Dist 25d
2 / 2
EPS YoY
+18.0%
LoD dist
12.0
Off 52w High
16.2%
Above 52w Low
75.8%
1W / 1M
-0.8 / +3.7
Avg $Vol 50d
421.7M
Mkt Cap (B)
42.3
Trend 8/8
no
Leads Group
YES
Sector XLV
+1.8% 1W
Base len (VCP)
10wk (11/11)
Coil (base shape)
85TVPX
What do these abbreviations mean?
- RS Rating
- - IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
- ADR%
- - average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
- RMV (tight)
- - Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
- Ext (ATR>20EMA)
- - how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
- Rel Vol
- - latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
- U/D 50d / 25d
- - up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
- Accum/Dist 25d
- - heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
- LoD dist
- - close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
- Off/Above 52w
- - trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
- Trend 8/8
- - all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
- Base len (VCP)
- - weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.
Fundamentals & valuation - reference, not entry inputs
P/E (TTM)
47.7
Fwd P/E
26.3
PEG
0.8
Price/Book
3.9
Profit margin
28.4%
ROE
13.9%
Debt/Equity
1.3
Rev growth
+16.0%
Analyst target
$264 (+2%)
Analyst rating
BUY
Institutional %
90.0%
Insider %
8.6%
Float %
92.2%
Valuation and analyst figures are Yahoo company stats (weekly refresh, ~3,000 larger names - blanks are honest gaps); logo, employees, website and IPO date are Massive company reference. Momentum/VCP entries do not use valuation - this card is context so you do not have to leave the page.
Company data - context read, not entry inputs
Industry rank
14 / 147
Industry
Health Information Services
Float
149.8M
Float turnover 20d
1.3%
Avg $Vol 20d / 50d
527.3M / 421.7M
Days to cover
2.8
Short % float
3.9%
Institutional %
90.0%
Weinstein stage
2
Float, short interest and institutional % come from Yahoo company stats, refreshed weekly for ~3,000 larger names - a blank means Yahoo does not publish the figure for this stock, not that it is zero. Dollar volume and float turnover are computed from our own price bars; industry rank from our rotation data; stage from the weekly chart.
Quarterly EPS - earnings acceleration
A dash in %Chg is deliberate: the year-ago figure was a loss, so a growth % would be meaningless. A dash in Sales means we have no revenue figure for that quarter - read it as a gap in our data, not as zero revenue.
| Quarter | EPS ($) | %Chg YoY | Sales ($M) | %Chg |
|---|---|---|---|---|
| Dec-24 | 1.75 | +31% | 699.2 | +13% |
| Mar-25 | 1.74 | +26% | 720.9 | +14% |
| May-25 | 1.97 | +31% | 759.0 | +17% |
| Aug-25 | 1.99 | +23% | 789.1 | +17% |
| Nov-25 | 2.04 | +17% | 811.2 | +16% |
| Mar-26 | 2.06 | +18% | 836.0 | +16% |
| Jun-26 | 2.24 | +14% | 882.9 | +16% |
| Aug-26 | 2.35 | +18% | 928.0 | +18% |
† = SEC carries this same fiscal quarter under a second period-end with a materially different figure (hover for it) - a restatement, merger recast or successor-period split; %Chg is blanked when the two are more than 15% apart. It fires only when the two period-ends DISAGREE, so it is a floor, not a guarantee that the rest of the column shares one basis · ‡ = the revenue concept changed from the previous quarter WITH A FIGURE (hover for both) - a blank row in between is skipped, as the eye does - a step at that row is a change of basis, not necessarily of business · EPS = Yahoo
eps_actual (the figure MarketSmith/Deepvue show) - whether a given quarter is GAAP or excludes a one-off follows the filing, so it can sit either side of another vendor's number; AAPL's Oct-24 row, the Sep-2024 fiscal quarter, is $0.97 here - GAAP, including the EU tax charge - where TradingView's year implies $1.64 · Sales ($M) = SEC EDGAR quarterly revenue (fiscal Q4 derived as FY minus 9-mo) · quarter = report month · %Chg blank = prior-year base under $0.05 (not meaningful).Recent news - our DB (Finnhub + OVTLYR)
- Sep 18 + Quality Management System (QMS) Software Market Surges to $20.43 billion at a CAGR 11.7% by 2031 | Report by MarketsandMarkets™ GlobeNewswire Inc.
- Sep 03 + VEEV Raises FY27 Outlook as Vault CRM and AI Momentum Accelerate Fast Zacks Investment Research
- Sep 03 + The Market Just Told You Which Layer Of AI Biology It Is Paying For GlobeNewswire Inc.
- Sep 03 + Here's How Much You'd Have If You Invested $1000 in Veeva Systems a Decade Ago Zacks Investment Research
- Sep 02 + Veeva's Exiting President Sold $2.8 Million in Stock: What Investors Need to Know The Motley Fool
- Aug 31 · Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now? Zacks Investment Research
- Aug 27 + Veeva Systems Q2 Earnings and Revenues Beat Estimates, Stock Up Zacks Investment Research
- Aug 05 + [Latest] Global eClinical Solutions Market Size/Share Worth USD 42.55 Billion by 2035 at a 13.98% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) GlobeNewswire Inc.